This is a mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g., "parkinsonism_dopaminergic_degeneration#Nigrostriatal Dopaminergic Neurodegeneration", the key conformance target). It models the dopaminergic final common pathway of parkinsonism (HP:0001300) and is intended for Parkinson disease and the secondary/genetic parkinsonisms — drug- and toxin-induced parkinsonism (MPTP, manganese/manganism), and monogenic forms. The environmental neurotoxicants (rotenone, paraquat, MPTP, manganese) plug into the Mitochondrial Complex I Inhibition and Oxidative Stress node. Two intentional caveats: (1) alpha-synuclein/Lewy pathology is characteristic of Parkinson disease and the synucleinopathies but is not universal — MPTP and rotenone act primarily through complex I inhibition, so conforming nodes may omit the alpha-synuclein arm; (2) manganism is a partial exception in which the predominant lesion is in the globus pallidus rather than the nigrostriatal dopaminergic system, and it characteristically responds poorly to levodopa, yet it still converges on basal-ganglia motor-circuit dysfunction. This module is distinct from tauopathy-predominant atypical parkinsonism (e.g., progressive supranuclear palsy) and from the TDP-43 proteinopathy module.
Dopaminergic Neuronal Vulnerability and Toxic Insult
trigger
The shared initiating event is injury to the dopaminergic neurons of the substantia nigra pars compacta by converging genetic and environmental insults. Epidemiological and toxicological data implicate occupational and environmental neurotoxicants — the herbicide paraquat, the pesticide rotenone, the meperidine contaminant MPTP, and manganese — alongside monogenic causes, all targeting the same selectively vulnerable nigral dopaminergic population.
Downstream
-
Mitochondrial Complex I Inhibition and Oxidative Stress
Toxic and genetic insults converge on mitochondrial complex I inhibition and oxidative stress in dopaminergic neurons.
Mitochondrial Complex I Inhibition and Oxidative Stress
amplifier
The convergent biochemical lesion is impairment of mitochondrial electron transport chain complex I with consequent oxidative stress. Environmental parkinsonian toxins act here directly — MPTP (via MPP+), rotenone, and paraquat inhibit or poison complex I — while monogenic PD genes (PINK1, PRKN, DJ-1) compromise mitochondrial quality control. The energy deficit and reactive oxygen species generation render the highly metabolically demanding nigral dopaminergic neurons selectively vulnerable. This node is where the environmental exposome plugs into the module.
Downstream
-
Alpha-Synuclein Aggregation and Lewy Pathology
Oxidative and bioenergetic stress promotes alpha-synuclein misfolding and aggregation in the synucleinopathy forms.
-
Nigrostriatal Dopaminergic Neurodegeneration
Complex I inhibition and oxidative stress directly drive death of vulnerable nigral dopaminergic neurons.
Alpha-Synuclein Aggregation and Lewy Pathology
central effector
In Parkinson disease and the synucleinopathy forms of parkinsonism, misfolded alpha-synuclein accumulates into Lewy bodies and Lewy neurites that spread in a prion-like manner and amplify dopaminergic injury. This proteostatic arm is characteristic of Parkinson disease but is not universal across all parkinsonisms — toxin models such as MPTP can produce nigral degeneration with variable alpha-synuclein pathology — so conforming nodes may include or omit it.
Downstream
-
Nigrostriatal Dopaminergic Neurodegeneration
Alpha-synuclein aggregation amplifies degeneration of nigral dopaminergic neurons.
Nigrostriatal Dopaminergic Neurodegeneration
effector
The convergent effector lesion is progressive degeneration of the substantia nigra pars compacta dopaminergic neurons and their nigrostriatal projection. This is the key conformance target of the module: motor parkinsonism emerges once nigral dopaminergic loss removes nigrostriatal dopamine input below a compensable threshold. Conforming disorders substitute their specific upstream driver while sharing this nigrostriatal degeneration.
Downstream
-
Striatal Dopamine Deficiency and Basal Ganglia Circuit Dysfunction
Loss of the nigrostriatal projection depletes striatal dopamine and unbalances the basal ganglia motor circuit.
Striatal Dopamine Deficiency and Basal Ganglia Circuit Dysfunction
effector
Loss of nigrostriatal dopaminergic terminals depletes dopamine in the striatum, the principal input nucleus of the basal ganglia. Reduced striatal dopamine shifts the basal ganglia-thalamocortical motor circuit toward excessive inhibitory output (hyperactive indirect pathway, hypoactive direct pathway), producing the cardinal features of parkinsonism (HP:0001300) — bradykinesia, rigidity, and rest tremor. In the dopaminergic parkinsonisms this circuit deficit is levodopa-responsive; manganism is a partial exception with predominantly pallidal pathology and poor levodopa response.
Used by disorders
Manganism
as Basal Ganglia Circuit Dysfunction and Extrapyramidal Parkinsonism